MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.43 +0.67 (+0.58%)
Official Closing Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
From Merck & Co., Inc.
Via Business Wire
Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors ↗
Via Chartmill
Technical Breakout Setup for Merck & Co. Inc. (NYSE:MRK) ↗
Via Chartmill
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call
Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗
On Feb. 9, 2026, Oracle's AI-fueled advance helped steady major U.S. indexes as software lagged and traders eyed key macro data. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗
You always get what you pay for, so don't be afraid to pay up for a little more quality. 
Via The Motley Fool
Topics Economy Intellectual Property Stocks
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal
In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially.... 
Via MarketMinute
Topics Economy Government Immigration
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
Via Stocktwits
Topics Economy Government World Trade
News headline image
USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New... 
Via MarketMinute
Topics Death Economy
AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda ↗
Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside. 
Via Stocktwits
Topics Earnings Intellectual Property
News headline image
MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
News headline image
Merck (MRK) Q4 2025 Earnings Call Transcript ↗
Merck (MRK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
Topics Earnings
News headline image
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Merck (MRK) Q4 Earnings Report Preview: What To Look For
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
This genomics stock appears to be at an inflection point. 
Via The Motley Fool
Topics Earnings
News headline image
2 Cash-Producing Stocks to Target This Week and 1 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
This Stock Is Already Up 58% This Year. Is It a Buy? ↗
This forgotten pandemic stock hasn't said its last word. 
Via The Motley Fool
News headline image
Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility
As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
The $4 Billion Avatar: How Synthesia is Defining the Era of Agentic Enterprise Media
In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on... 
Via TokenRing AI
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story